Results 221 to 230 of about 6,101 (249)

Intrathecal delivery of nusinersen in individuals with complicated spines

Muscle & Nerve, 2020
AbstractBackgroundThe treatment of spinal muscular atrophy (SMA) with nusinersen requires intrathecal medication administration, which can be challenging in individuals with complicated spines. This retrospective case series reviews the nusinersen treatment experience at one academic medical center with children and adults with SMA and complicated ...
Thomas G. West, Michael S. Cartwright, Zachary T. Ward, Eric P. White   +3 more
openaire   +2 more sources

Treating adults with spinal muscular atrophy with nusinersen

Journal of Neurology, Neurosurgery & Psychiatry, 2020
Nusinersen was the first drug approved to treat people with spinal muscular atrophy (SMA), based on clinical data obtained from the initial trials undertaken in infants and children.1 2 With limited evidence of the safety and efficacy of nusinersen across the spectrum of ages and severities in SMA, adult patients are now confronting uncertain ...
Michelle A Farrar, Matthew C Kiernan
openaire   +3 more sources

Ultrasound-guided cervical puncture for nusinersen administration in adolescents

Pediatric Radiology, 2018
Spinal muscular atrophy (SMA) is an autosomal-recessive disease affecting motor neurons and is the most common genetic cause of death in infants. Intrathecal nusinersen is the only therapy approved by the U.S. Food and Drug Administration for SMA.
Timothy Lotze, Timothy Lotze, Carlos B Ortiz, Alex Chau, Alex Chau, Kamlesh Kukreja, Kamlesh Kukreja   +6 more
openaire   +3 more sources

Nusinersen treatment response markers

Nature Reviews Neurology, 2022
openaire   +2 more sources

Ergebnisse zu Nusinersen [PDF]

InFo Neurologie & Psychiatrie, 2018
openaire   +1 more source

Plecanatide, Nusinersen, and Obeticholic acid

Journal of the American Pharmacists Association, 2017
Daniel A. Hussar, Deborah K. Douglas
openaire   +3 more sources

Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy

Nature Neuroscience, 2017
Nusinersen (Spinraza) is a recently approved drug for treating spinal muscular atrophy. Approval of nusinersen may signal new opportunities for using antisense oligonucleotides as treatments for devastating neurological diseases.
openaire   +2 more sources

A CSF marker of nusinersen treatment response

Nature Reviews Neurology, 2022
openaire   +2 more sources

Nusinersen treatment of Spinal Muscular Atrophy Type 1 — results of expanded access programme in Poland

Neurologia I Neurochirurgia Polska, 2021
Sandra Modrzejewska, Anna Lemska, Ilona Kopyta   +2 more
exaly  

Intrathecal nusinersen administration: Is anesthesia really needed?

Pediatric Anesthesia, 2021
Anna Camporesi, Anna Mandelli, Elisa Melloni   +2 more
openaire   +3 more sources